Boston Scientific Corporation: EPS $0.73 vs $0.718 expected; revenue $5.14B vs $5.06B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.730 | 0.718 | +1.7% | 0.750 |
| Revenue (USD bn) | 5.140 | 5.060 | +1.5% | 5.070 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | Q3 FY2026 | 0.73 | 0.718 | +1.7% | 5.14 | 5.06 | +1.5% |
| Jul 29, 2026 | Q2 FY2026 | 0.86 | 0.835 | +3.0% | 5.44 | 5.38 | +1.2% |
| Apr 22, 2026 | Q1 FY2026 | 0.80 | 0.788 | +1.5% | 5.20 | 5.17 | +0.6% |
| Feb 4, 2026 | Q4 FY2025 | 0.80 | 0.781 | +2.4% | 5.29 | 5.28 | +0.1% |
| Oct 22, 2025 | Q3 FY2025 | 0.75 | 0.714 | +5.0% | 5.07 | 4.97 | +1.9% |
| Jul 23, 2025 | Q2 FY2025 | 0.75 | 0.725 | +3.4% | 5.06 | 4.89 | +3.4% |
| Apr 23, 2025 | Q1 FY2025 | 0.75 | 0.673 | +11.4% | 4.66 | 4.57 | +2.0% |
| Feb 5, 2025 | Q4 FY2024 | 0.70 | 0.657 | +6.5% | 4.56 | 4.42 | +3.2% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Boston Scientific Corporation results: EPS $0.73 vs $0.718 expected; revenue $5.14B vs $5.06B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 1.7%; revenue above the estimate by 1.5%.
Revenue was up 1.4% from $5.07 billion a year earlier (Q3 FY2025). EPS was down 2.7% from $0.75 a year earlier. On its record, EPS topped analysts' estimates in 7 of 7 earlier comparable reports.
What the results mean
Boston Scientific Corporation operates across a diverse range of medical devices used in interventional care, spanning cardiovascular and rhythm disorders, gastrointestinal and urological conditions, and neurological diseases. This breadth creates sources of demand tied to varied treatment needs, making product adoption across medical specialties central to understanding its business.
Revenue growth is linked to the company's ability to translate its technologies into sustained clinical use. Business drivers include adoption of catheters, cardiac rhythm management devices, and neurostimulation technologies, but the available information does not establish each area's contribution to the results or explain changes in profitability.
What to watch on the earnings call: Watch management's comments on demand across medical specialties, adoption of cardiovascular and neurostimulation technologies, and the contribution of product mix to margins. Discussion of device development spending and the ability to meet demand would also help clarify the relationship between business growth and profitability.
For the full analysis of Boston Scientific Corporation stock — valuation, scores and financial statements — see the stock page linked with this story.